The evolving role of radiation in pancreatic cancer

被引：11

作者：

Malla, Midhun ^{[1
]}

Fekrmandi, Fatemeh ^{[2
]}

Malik, Nadia ^{[2
]}

Hatoum, Hassan ^{[3
]}

George, Sagila ^{[3
]}

Goldberg, Richard M. M. ^{[1
]}

Mukherjee, Sarbajit ^{[4
]}

机构：

[1] West Virginia Univ, Canc Inst, Morgantown, WV USA

[2] Roswell Pk Comprehens Canc Ctr, Dept Radiat Med, Buffalo, NY USA

[3] Univ Oklahoma Hlth Sci Ctr, Stephenson Canc Ctr, Hematol Oncol, Oklahoma City, OK USA

[4] Roswell Pk Comprehens Canc Ctr, Dept Med, GI Med Oncol, Buffalo, NY 14203 USA

来源：

FRONTIERS IN ONCOLOGY | 2023年 / 12卷

关键词：

pancreatic cancer; chemo; radiotherapy; radiation; resectability; radiation techniques; PHASE-III TRIAL; GEMCITABINE; CHEMORADIOTHERAPY; CHEMOTHERAPY; SURVIVAL; CHEMORADIATION; ERLOTINIB; 5-FU;

D O I：

10.3389/fonc.2022.1060885

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pancreatic cancer is the fourth leading cause of cancer mortality in the United States. Chemotherapy in resectable pancreatic cancer has improved survival by 10-20%. It only converted 10-30% of the borderline resectable and locally advanced pancreatic cancers to be surgically resectable. Radiation therapy has a documented role in managing localized pancreatic cancer, more so for borderline and locally advanced pancreatic cancer, where it can potentially improve the resectability rate of a given neoadjuvant treatment. The role of radiation therapy in resected pancreatic cancer is controversial, but it is used routinely to treat positive margins after pancreatic cancer surgery. Radiation therapy paradigms continue to evolve with advancements in treatment modalities, delivery techniques, and combination approaches. Despite the advances, there continues to be a controversy on the role of radiation therapy in managing this disease. In this review article, we discuss the recent updates, delivery techniques, and motion management in radiation therapy and dissect the applicability of this therapy in pancreatic cancer.

引用

页数：10

共 36 条

[1] Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question-Erlotinib plus Gemcitabine for Resected Cancer of the Pancreatic Head A Phase II Randomized Clinical Trial [J].

Abrams, Ross A. ;

Winter, Kathryn A. ;

Safran, Howard ;

Goodman, Karyn A. ;

Regine, William F. ;

Berger, Adam C. ;

Gillin, Michael T. ;

Philip, Philip A. ;

Lowy, Andrew M. ;

Wu, Abraham ;

DiPetrillo, Thomas A. ;

Corn, Benjamin W. ;

Seaward, Samantha A. ;

Haddock, Michael G. ;

Song, Suisui ;

Jiang, Yixing ;

Fisher, Barbara J. ;

Katz, Alan W. ;

Mehta, Sharmila ;

Willett, Christopher G. ;

Crane, Christopher H. .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2020, 43 (03) :173-179

[2] FAILURE TO ADHERE TO PROTOCOL SPECIFIED RADIATION THERAPY GUIDELINES WAS ASSOCIATED WITH DECREASED SURVIVAL IN RTOG 9704-A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AND CHEMORADIOTHERAPY FOR PATIENTS WITH RESECTED ADENOCARCINOMA OF THE PANCREAS [J].

Abrams, Ross A. ;

Winter, Kathryn A. ;

Regine, William F. ;

Safran, Howard ;

Hoffman, John P. ;

Lustig, Robert ;

Konski, Andre A. ;

Benson, Al B. ;

Macdonald, John S. ;

Rich, Tyvin A. ;

Willett, Christopher G. .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (02) :809-816

[3]

Barin S., 2022, ENG SCI TECHNOL INT, V34, P101174, DOI 10.1089/genedge.2.1.54

[4] Influence of resection margins and treatment on survival in patients with pancreatic cancer -: Meta-analysis of randomized controlled trials [J].

Butturini, Giovanni ;

Stocken, Deborah D. ;

Wente, Moritz N. ;

Jeekel, Hans ;

Klinkenbijl, Johaness H. G. ;

Bakkevold, Kare E. ;

Takada, Tadahiro ;

Amano, Hirano ;

Dervenis, Christos ;

Bassi, Claudio ;

Buechler, Markus W. ;

Neoptolemos, John P. .

ARCHIVES OF SURGERY, 2008, 143 (01) :75-83

[5]

Chang DS., 2021, BASIC RADIOTHERAPY P, DOI [10.1007/978-3-030-61899-5_21, DOI 10.1007/978-3-030-61899-5_21]

[6]

Chang DS., 2021, BASIC RADIOTHERAPY P, P261, DOI [10.1007/978-3-030-61899-5_25, DOI 10.1007/978-3-030-61899-5_25, 10.1007/978-3-030-61899-525, DOI 10.1007/978-3-030-61899-525]

[7]

Chang DS., 2021, BASIC RADIOTHERAPY P, P231, DOI [10.1007/978-3-030-61899-5_22, DOI 10.1007/978-3-030-61899-5_22]

[8] Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer.: Definitive results of the 2000-01 FFCD/SFRO study [J].

Chauffert, B. ;

Mornex, F. ;

Bonnetain, F. ;

Rougier, P. ;

Mariette, C. ;

Bouche, O. ;

Bosset, J. F. ;

Aparicio, T. ;

Mineur, L. ;

Azzedine, A. ;

Hammel, P. ;

Butel, J. ;

Stremsdoerfer, N. ;

Maingon, P. ;

Bedenne, L. .

ANNALS OF ONCOLOGY, 2008, 19 (09) :1592-1599

[9] Elective Target Coverage for Pancreatic Cancer: When Less Does Not Clearly Achieve More [J].

Chuong, Michael D. ;

Kharofa, Jordan ;

Sanford, Nina N. .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 112 (01) :143-145

[10] Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer [J].

Cuneo, Kyle C. ;

Morgan, Meredith A. ;

Sahai, Vaibhav ;

Schipper, Matthew J. ;

Parsels, Leslie A. ;

Parsels, Joshua D. ;

Devasia, Theresa ;

Al-Hawaray, Mahmoud ;

Cho, Clifford S. ;

Nathan, Hari ;

Maybaum, Jonathan ;

Zalupski, Mark M. ;

Lawrence, Theodore S. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (29) :2643-+

← 1 2 3 4 →